MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

Search

Charles River Laboratories International Inc

Atvērts

SektorsVeselības aprūpe

173.14 2.12

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

167.41

Max

173.94

Galvenie mērījumi

By Trading Economics

Ienākumi

27M

53M

Pārdošana

48M

1B

P/E

Sektora vidējais

592.3

35.739

Peļņas marža

5.105

Darbinieki

18,700

EBITDA

37M

221M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+3.66% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-936M

7.3B

Iepriekšējā atvēršanas cena

171.02

Iepriekšējā slēgšanas cena

173.14

Ziņu noskaņojums

By Acuity

4%

96%

2 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. okt. 16:58 UTC

Peļņas

BMW Trims 2025 View, Citing Weaker Performance in China

2025. g. 7. okt. 23:43 UTC

Tirgus saruna

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025. g. 7. okt. 23:36 UTC

Tirgus saruna

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025. g. 7. okt. 23:19 UTC

Tirgus saruna

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025. g. 7. okt. 22:40 UTC

Tirgus saruna

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025. g. 7. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 20:44 UTC

Karstas akcijas

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025. g. 7. okt. 19:42 UTC

Tirgus saruna

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025. g. 7. okt. 19:23 UTC

Iegādes, apvienošanās, pārņemšana

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025. g. 7. okt. 19:07 UTC

Tirgus saruna

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025. g. 7. okt. 19:02 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 7. okt. 15:37 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 15:37 UTC

Tirgus saruna

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025. g. 7. okt. 15:33 UTC

Tirgus saruna

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025. g. 7. okt. 15:25 UTC

Tirgus saruna

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025. g. 7. okt. 15:15 UTC

Tirgus saruna

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025. g. 7. okt. 15:04 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 7. okt. 15:04 UTC

Tirgus saruna

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025. g. 7. okt. 14:56 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 14:56 UTC

Tirgus saruna

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025. g. 7. okt. 14:52 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

3.66% augšup

Prognoze 12 mēnešiem

Vidējais 176.33 USD  3.66%

Augstākais 200 USD

Zemākais 160 USD

Pamatojoties uz 15 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

15 ratings

7

Pirkt

8

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

2 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat